• Oshkosh Corporation recently reported second-quarter 2026 results showing sales of US$2,915.1 million and diluted EPS from continuing operations of US$2.92, while also updating its full-year 2026 outlook to approximately US$11.2 billion in net sales and declaring a quarterly dividend of US$0.57 per share payable on August 27, 2026.
• Alongside these results, Oshkosh disclosed further progress on its long-running buyback program, having repurchased 667,158 shares for US$91.6 million in the latest quarter and completed the repurchase of 19,552,641 shares since 2015, which could influence how investors view its capital return priorities and earnings profile.
• Now we’ll examine how Oshkosh’s raised 2026 sales guidance and ongoing share repurchases may influence the company’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Oshkosh Investment Narrative Recap

To own Oshkosh, you need to believe its specialized vehicles and long-term government and infrastructure demand can support solid earnings through cycles, despite exposure to tariffs, defense budgets and construction swings. The latest quarter showed higher sales but lower earnings, and the higher 2026 sales outlook does not materially change that the key near term catalyst remains execution on large contracts, while the biggest risk is still potential volatility in government funding and construction activity.

The most relevant update here is Oshkosh’s fuller-year 2026 guidance, which now points to about US$11.2 billion in net sales. That higher sales outlook, combined with ongoing buybacks, ties directly into the existing catalyst that contract execution and capacity utilization could support earnings. At the same time, the guidance reminds you that margins can move around even when revenue is growing, which matters if cost pressures or end markets soften again.

Yet beneath the higher sales guidance, investors should also be aware that Oshkosh’s dependence on large U.S. defense and postal contracts could...

Oshkosh's narrative projects $12.8 billion revenue and $1.1 billion earnings by 2029. This requires 6.5% yearly revenue growth and about a $543.7 million earnings increase from $556.3 million today.

Uncover how Oshkosh's forecasts yield a $167.25 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue of about US$13.2 billion and earnings near US$1.2 billion by 2029, so this new guidance and buyback progress might either reinforce that upbeat view or prompt a rethink of how realistic such margin and defense contract expectations really are.

Explore 3 other fair value estimates on Oshkosh - why the stock might be worth as much as 34% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Oshkosh research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Oshkosh research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oshkosh's overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.